News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A Small Stink for Amarin Corporation PLC (AMRN)'s Controversial Fish Oil Pill?


9/13/2013 8:35:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The latest twist in the prescription fish-oil saga emerged today when a federal appeals court issued a ruling that clears the way for generic versions of Lovaza, which has been a $1 billion seller for GlaxoSmithKline GSK +0.1% (here is the ruling). The news, however, was taken by some investors to be a big challenge for Amarin, a much-smaller player that sells the rival Vascepa pill.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes
Read at PharmaLive


comments powered by Disqus
Forbes
PharmaLive
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES